Karine Tawagi, MD, from the University of Illinois, discusses her work in immune-related toxicities. The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial. Neeraj Agarwal, MD, FASCO, describes positive data from the TALAPRO-2 study on talazoparib and enzalutamide for mCRPC. Michael Morris, MD discusses PARP inhibition for castration-resistant prostate cancer and the differing opinions on its use. The Uromigos discuss the cost of quality adjusted life years with Daniel Goldstein, MD, from Davidoff Cancer Center. A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference. Chris Sweeney, MBBS, joins The Uromigos to discuss 2022 research as well as further studies to be carried out in 2023. Drs. Silke Gillessen and Dan George debate the use of olaparib and abiraterone in selected or unselected patients with mCRPC. The Uromigos chat with Axel Merseburger about his paper on continuing enzalutamide with docetaxel for the treatment of CRPC. Rob Jones discusses the current state of PARP inhibition in prostate cancer as well as differing opinions on the treatment. Silke Gillessen and Nick James discuss a randomized trial on duration of adjuvant/salvage androgen ablation with XRT. Alex Wyatt joins The Uromigos to answer questions about ctDNA in prostate cancer and discuss his latest paper on that topic. Declan Murphy and Matt Cooperberg debate the use of interventions in active surveillance for patients with prostate cancer. Dr. Oliver Sartor, medical director of Tulane Cancer Center, discusses his career development and work in prostate cancer. Neal Shore describes his recent controversial paper and the over-treatment of patients with low-grade disease. Phillip Kuo discusses phase 3 of the VISION trial that utilizes Lutetium-177 for the treatment of prostate cancer. Drs. Rana McKay and Kim Chi question whether doublet or triplet therapy is appropriate in the first-line. Martin Stockler describes the ENZAMET trial, which shows mixed effects of enza on QOL in prostate cancer. Dr. Stefano Fanti focuses on PSMA therapy PET CT, particularly when to use this as a diagnostic. Dr. Fred Saad describes the results of the PROpel Phase III trial.